Ontology highlight
ABSTRACT:
SUBMITTER: Remon J
PROVIDER: S-EPMC6549681 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Cancer management and research 20190529
Immune checkpoint inhibitors (ICI) as monotherapy in selected patients as well as in combination with chemotherapy have become the standard of care in the first-line treatment strategy of advanced non-small cell lung cancer (NSCLC) patients. Combination treatment with ICI, such as nivolumab and ipilimumab or durvaluamb and ipilimumab, has also been proposed as potential strategies in this setting in selected advanced NSCLC patients. Characterizing predictive markers of long-term clinical benefit ...[more]